IS6263A - Lyfjasamsetningar, sem innihalda trípeptíð - Google Patents

Lyfjasamsetningar, sem innihalda trípeptíð

Info

Publication number
IS6263A
IS6263A IS6263A IS6263A IS6263A IS 6263 A IS6263 A IS 6263A IS 6263 A IS6263 A IS 6263A IS 6263 A IS6263 A IS 6263A IS 6263 A IS6263 A IS 6263A
Authority
IS
Iceland
Prior art keywords
pharmaceutical formulations
formulations containing
containing tripeptide
tripeptide
pharmaceutical
Prior art date
Application number
IS6263A
Other languages
English (en)
Inventor
Vahlne Anders
Original Assignee
Tripep Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripep Ab filed Critical Tripep Ab
Publication of IS6263A publication Critical patent/IS6263A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • C07K5/0817Tripeptides with the first amino acid being basic the first amino acid being Arg
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IS6263A 1999-08-09 2002-02-08 Lyfjasamsetningar, sem innihalda trípeptíð IS6263A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14798199P 1999-08-09 1999-08-09
PCT/IB2000/000972 WO2001010457A2 (en) 1999-08-09 2000-06-29 Pharmaceutical compositions containing tripeptides

Publications (1)

Publication Number Publication Date
IS6263A true IS6263A (is) 2002-02-08

Family

ID=22523732

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6263A IS6263A (is) 1999-08-09 2002-02-08 Lyfjasamsetningar, sem innihalda trípeptíð

Country Status (16)

Country Link
US (1) US20030050242A1 (is)
EP (1) EP1207897A2 (is)
JP (1) JP2003506411A (is)
KR (1) KR20020019126A (is)
CN (1) CN1377276A (is)
AU (1) AU5701300A (is)
CA (1) CA2378480A1 (is)
CZ (1) CZ2002421A3 (is)
HU (1) HUP0202512A2 (is)
IL (1) IL147970A0 (is)
IS (1) IS6263A (is)
MX (1) MXPA02001349A (is)
NO (1) NO20020635L (is)
PL (1) PL354122A1 (is)
RU (1) RU2002102868A (is)
WO (1) WO2001010457A2 (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US6593455B2 (en) 2001-08-24 2003-07-15 Tripep Ab Tripeptide amides that block viral infectivity and methods of use thereof
US6455670B1 (en) 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof
EP1436317A1 (en) 2001-09-19 2004-07-14 Tripep Ab Molecules that block viral infectivity and methods of use thereof
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
TWI411441B (zh) * 2003-03-18 2013-10-11 Suntory Holdings Ltd 血管收縮素轉化酶抑制性肽類
EP1608281B1 (en) 2003-04-03 2016-07-13 Galil Medical Ltd. Apparatus for accurately delimited cryoablation
KR101215821B1 (ko) 2003-06-30 2012-12-28 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. 아밀로이드 관련 질환을 진단 및 처치하기 위한 펩타이드, 그것에 대한 항체, 및 그 사용방법
WO2005027901A1 (en) 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
WO2006018850A2 (en) 2004-08-19 2006-02-23 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
JP4846799B2 (ja) 2005-07-05 2011-12-28 バイオテンプト ベー.フェー. 腫瘍の治療
EP1973928A2 (en) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
DE102005050557A1 (de) * 2005-10-17 2007-04-19 Universität Tübingen SRF als diagnostisches und/oder therapeutisches Target für Erkrankungen, die mit neuronalen Abnormalitäten assoziiert sind
GB2433505A (en) * 2005-12-20 2007-06-27 Sharp Kk Capture agents for binding a ligand
GB2433591A (en) * 2005-12-20 2007-06-27 Sharp Kk Method for functionalising a hydrophobic substrate
GB2433506A (en) * 2005-12-20 2007-06-27 Sharp Kk A method of producing a multimeric capture agent
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US9463195B2 (en) * 2006-12-15 2016-10-11 The Regents Of The University Of California Dissolution of amyloid fibrils by flavonoids and other compounds
EP2170364A2 (en) * 2007-06-25 2010-04-07 Oncoreg AB Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
GB0716494D0 (en) * 2007-08-23 2007-10-03 Isis Innovation HIV-2 antigenic peptides
WO2010124262A1 (en) * 2009-04-24 2010-10-28 Allostera Pharma Inc. Methods of identification of allosteramers and uses thereof
WO2012066549A1 (en) 2010-11-15 2012-05-24 Ramot At Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
WO2012070971A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Косметологическая и фармацевтическая композиция для омоложения и восстанов- ления кожи, в том числе после хирургических операций
HU231182B1 (hu) * 2013-05-17 2021-08-30 Szegedi Tudományegyetem A ß-amiloid toxicitását gátló kis peptid inhibitorok
EP2913338A1 (en) 2014-02-28 2015-09-02 Roche Diagniostics GmbH Soluable and immunoreactive variants of HTLV capsid antigen p24
KR101693682B1 (ko) * 2014-03-21 2017-01-09 서울대학교병원 (분사무소) Acq를 포함하는 항산화용 화장품 조성물
CN104324359B (zh) * 2014-09-25 2016-08-17 中山大学 Rry三肽在制备治疗阿尔茨海默症药物中的用途
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
CN104258371B (zh) * 2014-09-25 2016-06-15 中山大学 Www三肽在制备治疗阿尔茨海默症药物中的用途
CA2963478A1 (en) * 2014-10-14 2016-04-21 Riptide Bioscience, Inc. Peptides having anti-inflammatory properties
GB201613999D0 (en) * 2016-08-16 2016-09-28 Neuro-Bio Ltd Neurodegenerative disorders
KR20230156265A (ko) * 2022-05-03 2023-11-14 한국생명공학연구원 신규 펩타이드 및 이의 항염 및 재생 용도

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1063727A (en) * 1912-07-31 1913-06-03 William J Pierce Bed-caster.
US4215112A (en) * 1979-03-14 1980-07-29 Ortho Pharmaceutical Corporation Tripeptides and methods
US4658013A (en) * 1981-07-28 1987-04-14 Sterling Drug Inc. Analgesic and/or opiate antagonist tripeptide amides and processes for preparation and compositions thereof
CS231228B1 (en) * 1982-10-01 1984-10-15 Evzen Kasafirek Biologically effective tri and tetrapeptide alkylamide derivatives and their processing method
US4857538A (en) * 1987-11-30 1989-08-15 The Research Foundation Of State University Of New York New compounds for the study and treatment of microfilament organization in cells
US4950647A (en) * 1988-10-04 1990-08-21 Nucleic Acid Research Institute T cell immunopotentiator
IT1231342B (it) * 1989-08-28 1991-11-28 Prodotti Antibiotici Spa Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono
US5336758A (en) * 1990-03-09 1994-08-09 The United States Of America As Represented By The Department Of Health And Human Services Peptides stimulating cytotoxic T cells immune to HIV RT
DE4014655A1 (de) * 1990-05-08 1991-11-14 Behringwerke Ag Peptidamide, verfahren zu deren herstellung und diese enthaltende mittel als fibrin/thrombin-gerinnungsinhibitoren
US5627035A (en) * 1990-08-22 1997-05-06 Syntello Vaccine Development Ab Peptides that block human immunodeficiency virus and methods of use thereof
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
RO109653B1 (ro) * 1990-09-11 1995-04-28 Seikagaku Kogyo Co Ltd Polipeptide
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
JP3266311B2 (ja) * 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
NO921715L (no) * 1991-05-02 1992-11-03 Seikagaku Kogyo Co Ltd Nye polypeptider med affinitet for lipopolysakkarider og anvendelser derav
AU2140592A (en) * 1991-05-17 1992-12-30 Chiron Corporation Inhibitor of nf-kappa b transcriptional activator and uses thereof
US5856122A (en) * 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
FR2710340B1 (fr) * 1993-09-22 1995-12-15 D Hinterland Lucien Dussourd Dérivés peptidiques de l'alpha-MSH et leur application .
US5470951A (en) * 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
RU2136696C1 (ru) * 1993-10-14 1999-09-10 Сейкагаку Корпорейшн Новый полипептид и фармацевтическая композиция против вич-инфекции
US5744368A (en) * 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
ES2175083T3 (es) * 1995-03-14 2002-11-16 Praecis Pharm Inc Moduladores de la agregacion de amiloides.
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5770620A (en) * 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
US5932550A (en) * 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
US5872210A (en) * 1995-10-05 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Transframe peptide inhibitor of viral protease
US5830910A (en) * 1995-10-23 1998-11-03 University Of Kentucky Research Foundation Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
WO1997037228A1 (en) * 1996-03-29 1997-10-09 The Trustees Of Boston University Methods for diagnosing and treating alzheimer's disease
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US5886025A (en) * 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US5843995A (en) * 1997-07-07 1998-12-01 University Of Medicine And Dentistry Of New Jersey Inhibition of HIV-1 replication using oligocarbamate derivatives
US5952483A (en) * 1997-07-31 1999-09-14 Smithkline Beecham Corporation Human IκB-β
AU8912698A (en) * 1997-08-19 1999-03-08 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication using d-amino acid peptides
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof

Also Published As

Publication number Publication date
EP1207897A2 (en) 2002-05-29
JP2003506411A (ja) 2003-02-18
PL354122A1 (en) 2003-12-29
NO20020635D0 (no) 2002-02-08
RU2002102868A (ru) 2004-01-27
US20030050242A1 (en) 2003-03-13
NO20020635L (no) 2002-03-15
MXPA02001349A (es) 2002-07-22
KR20020019126A (ko) 2002-03-09
HUP0202512A2 (hu) 2002-11-28
WO2001010457A3 (en) 2001-08-30
IL147970A0 (en) 2002-09-12
AU5701300A (en) 2001-03-05
WO2001010457A2 (en) 2001-02-15
CA2378480A1 (en) 2001-02-15
CN1377276A (zh) 2002-10-30
CZ2002421A3 (cs) 2002-09-11

Similar Documents

Publication Publication Date Title
IS6263A (is) Lyfjasamsetningar, sem innihalda trípeptíð
IS2004B (is) Lyfjasamsetningar sem innihalda vorikónasól
NO20015175D0 (no) Farmasöytisk sammensetning
NO992339L (no) Farmasöytiske formuleringer
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
PT1242087E (pt) Composicoes farmaceuticas
ZA200200743B (en) Preserved pharmaceutical formulations.
GB0001662D0 (en) Pharmaceutical compositions
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
GB9923436D0 (en) Pharmaceutical compositions
ZA200000857B (en) Pharmaceutical composition.
PT1239832E (pt) Composicoes farmaceuticas
GB9904163D0 (en) Pharmaceutical compositions
IS6021A (is) Lyfjasamsetningar sem innihalda sítalópram
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
GB9911017D0 (en) Pharmaceutical compositions
HK1045102A1 (zh) 藥物配方
FI4488U1 (fi) Farmaseuttinen koostumus
HUP0201696A2 (en) Cyclic peptides, pharmaceutical compositions comprising thereof and their use
IL147731A0 (en) Peptide pharmaceutical formulations
GB9904911D0 (en) Pharmaceutical compositions
GB9906126D0 (en) Pharmaceutical formulations
GB9930578D0 (en) Pharmaceutical formulations
GB9902651D0 (en) Pharmaceutical compositions